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Abstract
Background: MYH9-related disease (MYH9-RD) is a rare autosomal dominant genetic syndrome characterized by congenital
thrombocytopenia associated with the risk of developing progressive nephropathy, sensorineural deafness, and presenile
cataract. During the collection of a large case-series of patients with MYH9-RD we noticed several cases with unexplained
elevation of liver enzymes. Our aim was to evaluate if the alteration of liver tests is a feature of the MYH9-RD and to define
its clinical significance.
Methods and Findings: Data concerning liver tests, prospectively recorded in the Italian Registry for MYH9-RD, were
collected and compared with those of three control populations: patients with autoimmune thrombocytopenia, patients
with inherited thrombocytopenias other than MYH9-RD, and the participants to a large epidemiologic survey in an Italian
geographic isolate. Thirty-eight of 75 evaluable MYH9-RD patients (50.7%) showed an elevation of ALT and/or AST, and 17 of
63 (27.0%) an increase of GGT. The increases ranged from 1.960.7 to 2.761.6 fold the upper normal limit. The prevalence of
liver test alterations was significantly higher in MYH9-RD patients than in each of the control populations, with odds ratios
ranging from 8.2 (95% CIs 2.2–44.8) to 24.7 (14.8–40.8). Clinical follow-up and more detailed liver studies of a subset of
patients, including ultrasound liver scan, liver elastography and liver biopsy in one case, did not show any significant
structural damage or evolution towards liver insufficiency.
Conclusions: Elevation of liver enzymes is a frequent and previously unrecognized feature of the MYH9-RD syndrome;
however, this defect does not appear to have poor prognostic value.
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Introduction
MYH9-related disease (MYH9-RD) is an autosomal dominant
disorder characterized by congenital thrombocytopenia with giant
platelets associated with the risk of developing progressive
nephropathy during infancy or adult life, sensorineural deafness
and presenile cataract [1,2]. MYH9-RD encompasses a series of
autosomal dominant macrothrombocytopenias previously consid-
ered as distinct disorders, namely May-Hegglin anomaly (MHA;
MIM#155100), Sebastian Syndrome (SBS; MIM#605249),
Fechtner Syndrome (FTNS; MIM#153640), and Epstein Syn-
drome (EPTS; MIM#135650), all deriving from mutations in the
MYH9 gene encoding for the heavy chain of nonmuscle myosin-
IIA (NMMHC-IIA) [1–5]. At least 44 different MYH9 mutations
have been reported so far [1,3–9], which may involve either the N-
terminal motor domain (MD) or the C-terminal tail domain (TD)
of NMMHC-IIA. Genotype-phenotype correlation studies have
shown that patients with mutations affecting the MD have more
severe thrombocytopenia and higher incidence of nephropathy
and deafness than those with mutations involving the TD [2].
Myosin-IIA is a non-sarcomeric myosin expressed in most cells
and tissues where it participates in functions associated with the
generation of chemomechanical forces by the cytoskeleton,
including cytokinesis, cell motility and maintenance of cell shape
[10,11]. Studies on the murine orthologue Myh9 have shown that
it is expressed in liver, kidney, lung and spleen and, at a lower
level, in heart and brain, with no expression in skeletal muscle and
testis [12]. Although congenital macrothrombocytopenia, sensori-
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recognized clinical hallmarks of the MYH9-RD syndrome,
previous studies have reported altered liver function tests in single
cases or small case series of patients with MYH9-RD [13–15].
During the collection of a large database of MYH9-RD patients
(Italian Registry for MYH9-RD, www.registromyh9.org) we
noticed several cases with unexplained elevated liver enzymes.
Aims of the present study were to carry out a systematic evaluation
of the prevalence of alterations of liver enzymes in a large, well-
characterized MYH9-RD population, to compare it with the
prevalence observed in a large population survey performed in
central eastern Sardinia [16] and in two populations of patients
with thrombocytopenias not related to MYH9 mutations studied
during the same period at the authors’ Centers, and to assess the
evolution of the liver test alterations in terms of potential organ
damage.
Methods
Patients
The study included all the consecutive patients enrolled in the
Italian Registry for MYH9-RD for which data concerning liver
function were available. Diagnosis of MYH9-RD was confirmed in
all patients by both immunofluorescence screening test and
molecular analysis [1,2,17]. Most patients have been already
reported (Table 1). The study was approved by the Ethic
Committee of the IRCCS Policlinico San Matteo Foundation,
Pavia; written informed consent was obtained from all the patients
or their legal guardians. As a control, data from the participants to
the Ogliastra cross-sectional epidemiologic survey, carried out in
central eastern Sardinia between with 2002 and 2008, were used
[16,18]. In addition, data of liver enzymes of MYH9-RD patients
were compared with those of two populations of consecutive
patients with MYH9-RD-unrelated thrombocytopenias studied
during the same period at the authors’ institutions, for which we
had single or repeated liver enzyme determinations: one with
acquired immune thrombocytopenia (ITP), the other with
different forms of inherited thrombocytopenia [19].
Liver studies in MYH9-RD patients
At the moment of the collection of data, the Italian Registry for
MYH9-RD included 184 patients. The following data were
extracted from the database: alanine aminotrasferase (ALT),
aspartate aminotrasferase (AST) and gamma-glutamyltransferase
(GGT). Elevation of liver enzymes was defined as a value above
the upper normal limit (UNL) of the reference laboratories where
the tests were carried out. The UNLs were established by the
participant laboratories based on the 95
th percentile distribution of
the serum concentrations of these enzymes in healthy blood
donors in their respective geographic areas. In all patients medical
history was recorded and physical examination was performed.
Moreover, whenever available the results of liver ultrasound
assessment and of additional biochemical tests were collected.
These latter included: viral hepatitis markers (antibodies to HCV,
Table 1. Genetic analysis of the 75 MYH9-RD patients described in this study.
Aminoacid change Nucleotide change n6 of patients (n6 of families)
Enrolled Previously reported Ref.
p.A95D c.284C.A 2 (1) 2 (1) 9
p.S96L c.287C.T 2 (2) 1 (1) 9
p.R702C c.2104C.T 11 (10) 9 (9) 9
p.R702H c.2105G.A 2 (2) 2 (2) 9
p.E1066-A1072del c.3195_3215del 1 (1) 1(1) 9
p.E1066-A1072dup c.3195_3215dup 1 (1) 1(1) 9
p.T1155I c.3464C.T 1 (1) 1 (1) 9
p.T1155A c.3463A.G 1 (1) 1 (1) 9
p.R1162T c.3485G.C 2 (2) 2 (2) 33
p.R1165C 3493C.T 4 (4) 3 (3) 9
p.R1165L c.3494G.T 2 (2) 1 (1) 9
p.D1424H c.4270G.C 7 (4) 7 (4) 9,34
p.D1424N c.4270G.A 2 (1) 2 (1) 9
p.D1424Y c.4270G.T 1 (1) none -
p.D1447V c.4340A.T 5 (2) 4 (1) 9
p.E1841K c.5521G.A 6 (3) 6 (3) 9
p.G1924RfsX21 c.5770_5779del 1 (1) 1 (1) 9
p.D1925TfsX23 c.5770delG 3 (1) 3 (1) 9
p.V1930CfsX18 c.5788delG 1 (1) 1 (1) 9
p.R1933X c.5797C.T 14 (8) 13 (7) 9
p.D1941MfsX7 c.5818delG 5 (2) 5 (2) 9
p.E1945X c.5833G.T 1 (1) 1 (1) 9
75 (52) 67 (44)
Abbreviations: Ref.=references.
doi:10.1371/journal.pone.0035986.t001
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clear antibodies, anti-smooth muscle cell antibodies, anti-mito-
chondrial antibodies, anti-LKM and anti-microsomal antibodies,
cupremia and plasma ceruloplasmin, serum a1-antitrypsin levels,
serum ferritin and saturated ferritin, thyroid hormones, and anti-
endomisium and anti-transglutaminase antibodies. All patients for
which a known cause of elevation of liver enzymes was identified
(e.g. infectious hepatitis, excessive alcohol intake, drug addiction,
gallstone disease, metabolic syndrome, celiac disease, congestive
heart failure, exposure to liver toxic agents) were excluded from
the analysis.
Liver transient elastography (Fibroscan) was carried out in two
patients and liver biopsy in one single case. Immunostaining for
NMMHC-IIA was performed on paraffin-embedded liver sections
by the PRB440P rabbit polyclonal antibody (Covance Research
Products, Berkeley, CA, USA) diluted 1:200 in PBS. The
horseradish peroxidase LSAB 2 kit (Dako, Glostrup, Denmark)
was used for secondary detection. The biopsy used as a control was
an unaffected liver sample collected as part of the diagnostic
procedures for clinical reasons unrelated to the present study and
processed for staining after patient’s informed consent.
Liver studies in the control populations
The criteria for defining liver enzymes elevation in the three
control populations were the same as for MYH9-RD patients. For
the Ogliastra inhabitants, data of serum GGT were not available.
For the participants to the Ogliastra survey, medical history was
collected by a physician at the time of measurement of liver
enzymes: subjects who referred a history of one of the known
causes of liver damage listed above were excluded from the study.
Statistical analysis
Continuous variables are reported as means 6 standard
deviation; categorical variables as total numbers and percentages.
We explored the distribution of liver enzymes levels in the different
patient populations examined. Possible associations between
alterations of liver enzymes and the specific MYH9 mutation, the
residue of the NMMHC-IIA protein affected by mutation, the
exon of MYH9 involved by mutation, or the involved domain were
investigated by Chi square test, after proper grouping of the
MYH9 mutations. Odds ratios (ORs) along with Chi square tests
were used to assess differences in liver enzyme alterations between
MYH9-RD patients and control populations, even excluding
patients who underwent transfusion or receiving specific drugs to
treat the clinical consequences of MYH9 mutations. In addition,
logistic regression was performed to take into account the potential
confounding effect of age and sex.
Results
Eighty-nine out of the 184 patients of the MYH9-RD registry
had liver function tests recorded. Fourteen of them were excluded
from the analysis because of the presence of an identifiable cause
of liver damage (positive serology for HBV or HCV, alcohol or
drug addiction, congestive heart failure).
Therefore, a total of 75 MYH9-RD patients belonging to 52
unrelated families were studied. Table 1 and 2 summarize their
basic genotypic and clinical features. Liver enzymes data were
compared with those of 7257 subjects from the Ogliastra
population, 77 patients with ITP, and 32 patients with different
forms of inherited thrombocytopenia not related to MYH9
mutations. These included monoallelic Bernard-Soulier syndrome
[19] (12 patients), autosomal-dominant thrombocytopenia deriv-
ing from ANKRD26 mutations [20](11 patients), autosomal-
dominant macrothrombocytopenia due to ITGB3 mutation [21]
(3 patients), and autosomal-dominant macrothrombocytopenia of
undefined origin (6 patients) [22,23]. Basic demographic features
of the study populations are summarized in Table 3.
Liver test alterations in the MYH9-RD population
Thirty-eight out of 75 MYH9-RD patients (50.7%) presented an
increase of AST or ALT in at least one determination (Table 4).
ALT was the most frequently altered aminotransferase, since it
was increased in 35 subjects (46.7%); twenty-nine of them (38.7%
Table 2. Basic clinical features of the 75 MYH9-RD patients
described in this study.
Gender - nu (%)
Female 43 (57%)
Male 32
Age - years
Mean 31.3
range 1–87
Position of MYH9 mutation - nu (%)
Motor domain 17 (23%)
Tail domain 58
Proteinuric nephropathy - nu (%)
Yes 20 (27%)
No 55
Sensorineural hearing loss - nu (%)
Yes 40 (53%)
No 35
Cataract - nu (%)
Yes 10 (13%)
No 65
Proteinuric nephropathy, sensorineural hearing loss, and cataracts were
evaluated as previously reported (Pecci et al, Hum Mutat 2008, reference 2).
doi:10.1371/journal.pone.0035986.t002
Table 3. Demographic characteristics of the study populations.
Population N6 Men (%) Age range [years] Mean age (SD) [years]
MYH9-RD 75 42.6 1–87 31.3 (19.9)
Other inherited thrombocytopenias 32 37.5 8–74 34.8 (19.4)
ITP 77 46.7 4–88 48.8 (24.8)
Ogliastra inhabitants 7257 45.4 3–105 43.2 (19.4)
doi:10.1371/journal.pone.0035986.t003
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(4%) showed an increase of only AST.
Serum GGT was measured in 63 cases and found to be
increased in 17 of them (27%). In particular, GGT was altered in
16 of the 32 evaluable subjects with an increase of aminotrans-
ferases (50%), while only one patient had isolated increase of
GGT. The mean increase of aminotransferases was 1.9 (SD 0.7)
fold the UNL for ALT and 1.4 (SD 0.4) for AST, while GGT were
increased 2.7 fold (SD 1.6).
Among patients with alteration of liver enzymes, a total of 29
subjects had liver enzymes measured repeatedly (from 1 to 9 times,
average 3.1, with intervals from 2 to 150 months, average 43.6
months) (Table 5). Out of these, 20 patients (69%) presented a
stable picture of enzymatic alteration, with increased liver enzymes
in all the measurements (mean number of repeated measurements,
2.9; mean interval, 34 months after the first measurement); four
patients (17%) had a fluctuating enzymatic pattern, with normal
findings at some of the intermediate measurements, while 5
patients (17%) experienced a normalization of the liver enzyme
alterations after a mean observation time of 19.2 months. In none
of the patients a clear worsening trend or a clinically relevant
alteration of liver function was observed.
Out of the 39 patients (belonging to 31 families) with alteration
of liver enzymes, 56% were males and had a mean age of 30.5
years; 9 patients were 16 years-old or less. MYH9-RD patients with
and without liver alterations did not differ significantly for gender,
platelet count, and presence of other extra-hematological mani-
festations of MYH9-RD; moreover, no association was found
between alterations of liver enzymes and patients’ age (data not
shown). There was no evident association between the elevation of
liver enzymes (prevalence or degree of elevation) and the specific
MYH9 mutation, the residue of the NMMHC-IIA protein affected
by mutation, or the involved domain (MD or TD, Figure 1).
However, when causative mutations were grouped by the involved
exon of MYH9, mutations of exon 25 (T1155I, T1155A, and
R1162T) were associated with a higher prevalence of elevation of
both aminotrasferases (p=0.04) and with a higher level of increase
of ALT (p=0.02); a nearly significant association was observed
also for a higher elevation of AST (p=0.07). A possible
cosegregation of mutations of exon 25 with altered liver enzymes,
however, needs confirmation since only 4 patients with mutations
involving this exon were analyzed.
Prevalence of liver test alterations in the control
populations
The prevalence of liver enzyme elevations in the Ogliastra
population is reported in Table 4. A total of 393 out of 7257
subjects presented an alteration of ALT or AST in at least one
determination (5.4%). The most frequent alteration was an
increase of ALT (320 subjects, 4.4%), and 139 cases (1.9%) had
a simultaneous increase of both aminotransferases. The remaining
73 subject (1.0%) showed an isolated elevation of AST. For
subjects with liver enzymes above normal, the mean value was
1.760.7 fold the UNL for ALT and 1.560.7 for AST.
In the control group of patients with ITP, 5 out of 77 patients
(6.5%) presented an alteration of ALT, while none of them had
increased AST (Table 4). An isolated elevation of GGT was
present in 4 of the 71 patients (5.6%) in which liver test was
performed. For subjects with liver enzymes above normal, the
average value was 1.3460.1 fold the UNL for ALT, and 1.4960.2
for GGT. When repeated enzyme measurements were carried out,
only 1/20 patients (5%) presented an alteration in at least two
determinations and none had a persistent alteration in all the
determinations carried out.
In the control group of patients with MYH9-unrelated inherited
thrombocytopenias, 3 out of 32 evaluable patients (9.4%) had an
increase of at least one aminotransferase (Table 4). The most
frequent alteration was an increase of ALT, which was present in
three subjects (9.4%), one of which had also elevated AST, while
none of the 26 evaluable patients had increased GGT. The mean
increase was 1.4860.12 fold the UNL for ALT and 2.18 for AST.
Table 4. Prevalence of liver enzyme alterations in the analyzed patient populations.
ALT AST At least one (ALT,AST) Both (ALT, AST) GGT
At least one
(ALT,AST,GGT)
MYH9-RD 35/75 (46.7%) 32/75 (42.7%) 38/75 (50.7%) 29/75 (38.7%) 17/63 (27.0%) 39/69 (56.5%)
Other inherited
thrombocytopenias
3/31 (9.7%) 1/30 (3.3%) 3/32 (9.4%) 1/29 (3.5%) 0/26 (0.0%) 3/26 11.5%)
ITP 5/77 (6.5%) 0/77 (0.0%) 5/77 (6.5%) 0/77 (0.0%) 4/71 (5.6%) 9/71 12.7%)
Ogliastra inhabitants 320/7257 (4.4%) 212/7257 (2.9%) 393/7257 (5.4%) 139/7257 (1.9%) N.A. N.A.
Data are presented as nu of patients with altered value/total nu of evaluable patients (%).
N.A.=not available.
doi:10.1371/journal.pone.0035986.t004
Table 5. Results of follow-up of 29 MYH9-RD patients with alterations of liver enzymes.
Liver enzyme
N6 of patients with alteration
at first measurement
N6 of patients with alterations
upon repeated measurements
N6 of altered
measurements/total n6
of measurements
Mean interval between repeated
measurements (range) [months]
AST 26 23 (88.4%) 86/115 (74.8%) 36.1 (2–150)
ALT 24 17 (70.8%) 58/111 (52.2%) 37.8 (2–150)
GGT 12 10 (88.3%) 34/78 (43.5%) 36.9 (5–120)
doi:10.1371/journal.pone.0035986.t005
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compared to each of the three different control populations ranged
from 8.2 to 18.9, to have an AST elevation from 21.6 to 24.7 and
to have an elevation of at least one of ALT or AST from 8.0 to
14.8 (p,0.0003, at least) (Table 6). The OR to have an elevation
of both aminotransferases ranged from 17.7 to 32.3 (p,0.0004, at
least). When adjusted for age and sex the ORs to have a liver test
alteration for MYH9-RD patients was even higher, ranging from
8.5 to 41.6 (not shown).
The analysis of the distribution curve of liver enzyme levels in
the different populations showed a markedly altered distribution in
MYH9-RD patients, with a flat, tendentially bimodal distribution
as compared with a rather typical Gaussian distribution in the
ITP, inherited thrombocytopenias and Ogliastra populations
(Fig. 2).
We also evaluated whether the increased prevalence of altered
liver enzymes in MYH9-RD patients could be due to a higher
prevalence of patients who underwent transfusion of blood
products and therefore exposed to transfusion-related liver
damage. In fact, 17 of the 75 investigated MYH9-RD patients
(22.6%), 26 of 77 ITP patients (33.8%) and 4 of 32 subjects with
other inherited thrombocytopenias (12.5%) had undergone
platelet or red blood cell transfusions (a prevalence of transfused
patients not significantly different between the three groups).
Medical history about transfusions was not available for the
Ogliastra population. The strongly increased prevalence and
degree of elevation of liver enzymes in MYH9-RD patients with
respect to each of the control populations was confirmed also when
the analysis was restricted to the patients who had never
undergone transfusions, even assuming that none of the subjects
of the Ogliastra population received transfusions. Limiting the
analysis to not transfused patients, the ORs to have a liver test
alteration for MYH9-RD patients as compared with the control
population ranged from 8.2 to 27.7 (p,0.001). Moreover, within
the MYH9-RD population, no significant difference in the
elevation of liver enzymes was observed between transfused and
non-transfused patients (data not shown), demonstrating that
previous transfusion did not exert a significant role in liver test
alterations in our case series.
Finally, we considered the hypothesis that the increased
frequency of markers of liver damage in MYH9-RD subjects
could be secondary to the confounding effect of potentially
hepatotoxic drugs administered to treat the clinical consequences
of the MYH9 mutations. In fact, 3 out of 75 MYH9-RD patients
were under immunosuppressive treatment for a previous kidney
transplantation and 8 were treated with ACE-inhibitors and/or
angiotensin receptor blockers for proteinuria [24]. However, the
strong association between MYH9 mutations and alterations of
liver enzymes was confirmed even when the analysis was restricted
to patients not receiving any permanent drug treatment (data not
shown).
Additional liver studies in patients with MYH9-RD
Twenty-one out of 39 (53.8%) MYH9-RD patients with liver test
abnormalities had a liver ultrasound examination carried out at
least once. Of these 18 had normal findings and 3 presented a mild
liver steatosis, defined as a ‘‘bright liver’’. Sometimes mildly
enlarged liver, with fine tightly packed echoes that made the liver
more echoic than the right kidney, was reported. Two patients had
liver transient elastography (Fibroscan) carried out on one
occasion: the median stiffness was within the normal range (F0).
Thirty-six of the 39 (92.3%) patients with altered liver tests had
serum tests for B and C hepatitis: all of them were negative.
A total of 21 patients underwent the more detailed biochemical
studies listed under methods: in all of them all these examinations
resulted normal.
Figure 1. Frequency of abnormal liver tests depending on the
location of the MYH9 gene mutation. Mutations involving the
motor domain and tale domain regions of the gene are indicated. No
significant differences in the distribution of liver test alteration between
the two locations of the gene defect were evident.
doi:10.1371/journal.pone.0035986.g001
Table 6. Odds ratio to have aminotransferase elevations in MYH9-RD patients as compared with the three control populations.
OR vs.
Enzyme
alterations ITP p-value
Other inherited
trombocyto-penias p-value
Ogliastra
inhabitants p-value
ALT 12.6 (4.4–43.8) 0.00001 8.2 (2.2–44.8) 0.0003 18.9 (11.5–31.0) 0.00001
AST N.A.
1 - 21.6 (3.2–908.3) 0.0001 24.7 (14.8–40.8) 0.00001
At least one (ALT or AST) 14.8 (5.1–51.3) 0.00001 9.9 (2.7–54.2) 0.0001 8.0 (4.9–12.9) 0.00001
Both (AST+ALT) N.A.
1 - 17.7 (2.6–746.1) 0.0004 32.3 (18.9–54.0) 0.00001
Data represent ORs (95% CIs).
N.A.=not available
Note:
1=Calculation of the OR is not possible since none of the 77 analysed ITP patients presented an elevation of AST.
doi:10.1371/journal.pone.0035986.t006
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35986In one patient, because of persistently elevated liver enzymes,
a laparoscopic liver biopsy was performed after prophylactic
transfusion of platelet concentrates. The patient was a 10-years-
old boy with the p.T1155A MYH9 substitution and a 6-years
history of persistently elevated ALT (59–303 U/L, UNL 38),
AST (54–141 U/L, UNL 38), and GGT (136–151 U/L, UNL
50). Serum alkaline phosphatase was also slightly elevated, while
bilirubin and cholinesterase were always within the normal
range. He underwent all the examinations listed above, plus
viral serology for HAV, CMV, EBV, cupruria, blood and urine
aminoacid, all of which resulted normal. Histopathology
revealed a preservation of hepatic architecture with scattered
hepatocytes showing micro-macrovacuolar steatosis. Mild fibro-
sis was evident in the portal spaces and around the terminal
veins. No inflammation, necrosis, apoptosis, regeneration or
cholestasis were detectable, and the copper content was normal.
Immunochemistry for NMMHC-IIA showed a positive reaction
concentrated close to the hepatocytes’ plasma membrane,
particularly in the region of bile canaliculi. Cholangiocytes
showed positivity mainly on the luminal side of plasma
membrane. No significant differences in NMMHC-IIA distri-
bution were detectable with respect to the liver biopsy used as a
control (Fig. 3).
Discussion
Our study in a large, well-characterized population of patients
with MYH9-RD, highlighted a high prevalence of unexplained
liver enzyme alterations, with over one half of patients showing
abnormal serum enzyme levels suggestive of possible liver damage.
The prevalence of liver enzyme alterations in this population
compares well or is even higher than that of the recognized non-
congenital manifestations of the MYH9-RD syndrome, namely
renal, hearing, and ocular defects, which are present in 16 to 60%
of MYH9-RD patients [2,6].
When compared with two different control populations of
patients with thrombocytopenias from different causes, one with
inherited thrombocytopenias other than MYH9-RD and the other
with immune thrombocytopenia, or with a large population of
people from a Sardinian geographic isolate, the ORs to have an
elevation of liver enzymes for MYH9-RD patients ranged from 8.2
to 24.7, a highly significant increased risk. When adjusted for age
and sex, the ORs were even higher, ranging from 8.5 to 41.6. No
associated causes of liver enzyme alterations were detected, even
upon more detailed liver studies, including repeated liver
ultrasound or in two cases liver elastography and in one liver
biopsy. Finally, a follow-up ranging from 2 to 150 months (mean
44) showed no trend towards a worsening of the observed liver test
alterations.
These data indicate that an elevation of liver enzymes is a
feature of the clinical spectrum of MYH9-RD, but that this
alterations seem benign, with no significant evolution towards
clinically relevant liver damage or dysfunction. Indeed, even in
MYH9-RD patients of an advanced age, in which an elevation of
liver enzymes was detected since the first diagnosis of their disease,
there was not one single case developing liver failure. Differently
from what happens with the other clinical features of the disease
which are more severe in patients carrying MYH9 mutations
affecting the MD of the protein, no clear genotype/phenotype
correlations were evident for the elevation of liver enzymes;
however, a possible cosegregation of the mutations involving exon
25 with altered liver enzymes seems to emerge but this needs
confirmation since only 4 patients with mutations involving this
exon were analyzed.
Our study has some potential limitations: MYH9-RD patients
may undergo platelet or blood transfusions more frequently than
healthy controls during their lifetime, and therefore they may
more prone to transfusion-related infectious liver injury. However,
the strongly increased prevalence of altered liver enzymes in
MYH9-RD patients was confirmed even when the analysis was
restricted to patients that had never received platelet or blood
transfusions. Moreover, the vast majority of our MYH9-RD
patients (92.3%) had been tested for B and C viral hepatitis, and all
those found positive were excluded from the analysis. In addition,
even assuming that the three subjects that had not been tested
were all HBV or HCV positive, the proportion of MYH9-RD
patients with unexplained liver enzyme elevation remains
significantly higher than that of controls (data not shown). Finally,
the possible confounding effect of potentially hepatotoxic drugs
administered to treat the clinical consequences of MYH9
mutations could reasonably be ruled out. Another limitation is
that a laboratory follow-up was available for only a fraction of the
MYH9-RD population and that follow-up was not of a sufficient
duration (maximum 150 months) to exclude a possible late
worsening of liver function. However, the observations that in a
Figure 2. Distribution of liver test levels in the four populations studied. Data for ALT, AST and GGT distributions are shown.
doi:10.1371/journal.pone.0035986.g002
Figure 3. Immunohistochemistry for NMMHC-IIA in the liver
biopsy from one patient with MYH9-RD. Liver biopsy from a 10-
years-old patient with MYH9-RD caused by the p.T1155A mutation of
MYH9 with persistently elevated AST, ALT and GGT. (A, B): Immuno-
histochemistry for NMMHC-IIA showed a signal (brown, horseradish
peroxidase staining) concentrated close to the hepatocytes’ plasma
membrane. The distribution of NMMHC-IIA was not significantly
different from that from a healthy control (C, D). Specimens were
counterstained with Meyer’s haematoxylin. Scale bars correspond to
10 mm.
doi:10.1371/journal.pone.0035986.g003
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more, not one single case evolved into liver failure/cirrhosis and
that imaging studies never showed significant liver structural
alterations suggest that liver test alterations in this genetic
syndrome do not lead to liver function impairment. This differs
from kidney involvement in MYH9-RD, which, when occurs,
tends to evolve progressively into end-stage renal failure [2,6]. Of
course a definitive conclusion on the benign course of liver
involvement in MYH9-RD requires confirmatory studies in large
case series with longer follow-up.
In the hepatocytes non-muscle myosin of class II has well-
recognized functions correlated with bile secretion. Myosin II was
found to be enriched in the actin microfilament network around
the bile canaliculus and was identified as the essential motor for
the bile canalicular contraction [25–27]. Moreover, myosin II is
involved in vesicle trafficking between the cytoplasmic compart-
ment and plasma membrane and regulates the apical membrane
expression of several transporters associated with bile secretion,
such as the bile salt export pump, whose genetic defects are
associated with some forms of familiar intrahepatic cholestasis
[28,29]. Recent studies identified additional key roles for myosin II
in hepatocytes, since it was implicated in postnatal hepatocytes
polyploidization [30] spatial reorganization of hepatocytes during
development and liver regeneration [31], and cell cycle progres-
sion and motility [32,33]. Although we have no data to provide a
mechanistic explanation of liver enzyme alterations in MYH9-RD,
the observation that the myosin IIA loss-of-function of MYH9-RD
patients primarily results in a phenotype consistent with
hepatocellular damage rather than a cholestatic disease seems
more consistent with the functions of myosin in hepatocyte
polyploidization, regeneration, cell cycle and motility [30–33].
In conclusion, our study shows that an alteration of liver
enzymes is a feature of the MYH9-RD syndrome, a defect however
that does not appear to have a poor prognostic value.
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